vasopharm GmbH today announces the results of significantly reduced brain microdialysate lactate levels in the phase 2 (NOSTRA) and phase 3 clinical trials (NOSTRA III) of Ronopterin (formerly VAS203) for the treatment of traumatic brain injury (TBI).
Read on Download PDFvasopharm GmbH today announces the finding of statistically significantly reduced brain microdialysate glutamate levels in the phase 2 (NOSTRA) and phase 3 clinical trials (NOSTRA III) of Ronopterin (formerly VAS203) for the treatment of traumatic brain injury (TBI).
Read on Download PDFvasopharm GmbH today announces the combined post hoc analyses of the phase 2 (NOSTRA) and phase 3 clinical trials (NOSTRA III) of Ronopterin (formerly VAS203) for the treatment of traumatic brain injury (TBI). These analyses expand on the clinically meaningful results in patients with moderate and severe TBI with early infusion of Ronopterin, starting between 6 and 12 hours after TBI. Ronopterin has the potential to be the first successful drug therapy for TBI with meaningful improvements in neurologic outcome.
Read on Download PDFPost-hoc analysis reveals clinically meaningful and statistically significant improvement in eGOS when ronopterin is infused within 12 hours after trauma. vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announces that the NOSTRA III traumatic brain injury (TBI) Phase III clinical trial of ronopterin (VAS203) did not meet the pre-specified primary endpoint of improvement in extended Glasgow Outcome Scale (eGOS) at six months after trauma.
Read on Download PDFvasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Prof Dr John F. Stover as Chief Medical Officer.
Read on Download PDFvasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce today that the Last Patient Last Visit (LPLV) in its phase 3 NOSTRA III clinical trial occurred on June 17, 2020
Read on Download PDF